5 results about "Atypical mycobacterium" patented technology

A novel CHI3L1 inhibitor provided in the present invention can efficiently inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1. In particular, it has been identified that K284-6111 can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1, and by newly synthesizing derivatives of K284-6111, novel compounds having a CHI3L1 inhibitory ability superior to that of K284-6111 have been identified. Therefore, the novel CHI3L1 inhibitors provided in the present invention can inhibit or treat disease progression of nontuberculous mycobacteria-infected lung diseases by inhibiting CHI3L1.

The chitinase 3-like 1 (CHI3L1) inhibitor, specifically kasugamycin, provided by the present invention, suppresses the expression or activation of chitinase 3-like 1 (CHI3L1), thereby effectively preventing or treating infections with acid-fast bacteria, particularly non-tuberculous mycobacteria and various diseases caused by infection with acid-fast bacteria, particularly nontuberculous mycobacteria. In addition, by measuring the expression level of chitinase 3-like 1 (CHI3L1) protein, when the expression level is higher than that of a control group, it is possible to effectively predict infection with acid-fast bacteria, particularly non-tuberculous mycobacteria, the onset of diseases caused by infection with acid-fast bacteria, particularly non-tuberculous mycobacteria, or the prognosis of diseases related to infection with acid fast bacteria, particularly nontuberculous mycobacteria.

This invention relates to combinations for treating nontuberculous mycobacterial diseases. Specifically, it relates to combinations of bedaquiline, macrolides (e.g., clarithromycin), and optionally ethambutol for use in the treatment of diseases associated with nontuberculous mycobacteria (NTM).

Provided herein are methods for preventing or treating an infection caused by a Nontuberculous mycobacterium (NTM) species in a subject comprising administering to the subject an effective amount of an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide. Also provided in are methods for sensitizing a biofilm to an antibiotic agent, wherein the biofilm comprises a Nontuberculous mycobacterium (NTM) species, the method comprising contacting the biofilm with an antibody or an antigen-binding fragment thereof that binds to a tip region of a DNABII peptide.

The present invention aims to provide a method for rapidly, simply, and reliably identifying patients with nontuberculous mycobacterial lung disease (pulmonary NTM disease) compared to lung cancer patients, healthy controls, or chronic airway inflammatory diseases other than pulmonary NTM disease, as well as a marker to be used in this method. [Solution] According to the present invention, it is possible to provide a biomarker consisting of the SLC26A4 gene, the SLC26A4 protein, or the SLC26A4-AS1 gene for distinguishing between subjects with pulmonary NTM disease and lung cancer patients or healthy controls or chronic airway inflammatory diseases other than pulmonary NTM disease, a method of identification using the gene or protein, and a kit containing the gene.